The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1

Sassi, Mouna; Chakroun, Tahar; Dreden, Patrick Van; Elalamy, Ismaı̈l; Larsen, Annette K.; Gerotziafas, Grigoris T.

doi:10.1177/1076029616665922

Cited by 5 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro assays demonstrate that certain tumour cells, including solid cancers [26,27,28,29,30] and haematological malignancies [26,28], can directly support thrombin generation. In some tumours, this is related to expression of TF.…”

Section: Tumour-specific Factors Contributing To Thrombin Generationmentioning

confidence: 99%

Thrombin Generation and Cancer: Contributors and Consequences

Reddel

Tan

Chen

2019

Cancers

View full text Add to dashboard Cite

The high occurrence of cancer-associated thrombosis is associated with elevated thrombin generation. Tumour cells increase the potential for thrombin generation both directly, through the expression and release of procoagulant factors, and indirectly, through signals that activate other cell types (including platelets, leukocytes and erythrocytes). Furthermore, cancer treatments can worsen these effects. Coagulation factors, including tissue factor, and inhibitors of coagulation are altered and extracellular vesicles (EVs), which can promote and support thrombin generation, are released by tumour and other cells. Some phosphatidylserine-expressing platelet subsets and platelet-derived EVs provide the surface required for the assembly of coagulation factors essential for thrombin generation in vivo. This review will explore the causes of increased thrombin production in cancer, and the availability and utility of tests and biomarkers. Increased thrombin production not only increases blood coagulation, but also promotes tumour growth and metastasis and as a consequence, thrombin and its contributors present opportunities for treatment of cancer-associated thrombosis and cancer itself.

show abstract

Section: Tumour-specific Factors Contributing To Thrombin Generationmentioning

confidence: 99%

Thrombin Generation and Cancer: Contributors and Consequences

Reddel

Tan

Chen

2019

Cancers

View full text Add to dashboard Cite

show abstract

“…The anticoagulant therapy also improves survival rates in these patients by an unknown mechanism. Inhibition of thrombin generation induced by low molecular weight heparins, LMWHs in cancer cells, depends mainly on the anti-Xa activity [ 190 ]. The most probable anticancer mechanisms mediated by heparin are inhibition of tumor cell/platelet/endothelial interactions to suppress cell invasion and angiogenesis [ 191 ].…”

Section: Thrombin Inhibitorsmentioning

confidence: 99%

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

Wojtukiewicz

Hempel²,

Sierko

et al. 2017

Cancer Metastasis Rev

View full text Add to dashboard Cite

The association between coagulation and cancer development has been observed for centuries. However, the connection between inflammation and malignancy is also well-recognized. The plethora of evidence indicates that among multiple hemostasis components, platelets play major roles in cancer progression by providing surface and granular contents for several interactions as well as behaving like immune cells. Therefore, the anticancer potential of anti-platelet therapy has been intensively investigated for many years. Anti-platelet agents may prevent cancer, decrease tumor growth, and metastatic potential, as well as improve survival of cancer patients. On the other hand, there are suggestions that antiplatelet treatment may promote solid tumor development in a phenomenon described as “cancers follow bleeding.” The controversies around antiplatelet agents justify insight into the subject to establish what, if any, role platelet-directed therapy has in the continuum of anticancer management.

show abstract